Emil D. Kakkis - 28 Feb 2025 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
President & CEO, Director
Signature
/s/ Karah Parschauer, attorney-in-fact
Issuer symbol
RARE
Transactions as of
28 Feb 2025
Net transactions value
-$4,153,571
Form type
4
Filing time
04 Mar 2025, 20:10:16 UTC
Previous filing
31 Dec 2024
Next filing
03 Mar 2026
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Award $0 +43,268 +7.7% $0.000000 607,873 01 Mar 2025 Direct F1
transaction RARE Common Stock Award $0 +107,292 +18% $0.000000 715,165 01 Mar 2025 Direct F2
transaction RARE Common Stock Sale $3,091,571 -73,434 -10% $42.10 641,731 03 Mar 2025 Direct F3, F4, F7
transaction RARE Common Stock Sale $1,062,000 -25,000 -1.1% $42.48 2,158,985 28 Feb 2025 By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RARE Stock Option (Right to Buy) Award $0 +78,448 $0.000000 78,448 01 Mar 2025 Common Stock 78,448 $42.92 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
F2 Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric.
F3 Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.89 to $42.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
F7 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.